Outcomes of Intense Pulsed Light Therapy for Treatment of Meibomian Gland Dysfunction

Sunday, April 19, 2015: 8:06 AM
Room 1B (San Diego Convention Center)
Gargi K. Vora, MD
Preeya K. Gupta, MD
Cynthia Matossian, MD, FACS

To determine the safety and clinical outcomes of intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction (MGD).

A retrospective chart review was performed of 82 patients with a diagnosis of meibomian gland dysfunction and dry eye syndrome that underwent IPL therapy from September 2012 to August 2014 at two outpatient eye centers. Demographics, clinical history, pre-treatment exam, and ocular surface disease index (OSDI) scoring data were collected from each visit. Data was analyzed using SAS analytical software.

The average age was 61 years and 71% were female. On average, patients underwent 4 IPL sessions (range 3-6).  From pre-treatment to final visit after IPL treatments, there was a statistically significant decrease in scoring of lid edema, facial telangiectasia, lid vascularity, meibiomian gland severity score, and OSDI score. There was also statistically significant increase in oil flow and tear break-up time. There were no significant changes in intraocular pressure or visual acuity.

IPL therapy for MGD is a safe procedure. The objective clinical exam findings and subjective OSDI scoring data suggest that IPL is an effective treatment for patients with MGD and resultant dry eye disease.